Postoperative Pain Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis
DelveInsight's, 'Postoperative Pain - Pipeline Insight, 2025' report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Postoperative Pain Pipeline constitutes 45+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analyzes DelveInsight.
Postoperative Pain Overview:
Postoperative or postsurgical pain is defined as pain persisting for more than 3 to 6 months after surgery, differing in nature and location from any pre-surgical pain. It is often associated with neuropathic pain caused by surgical injury to major peripheral nerves. While any surgery can result in persistent postoperative pain (PPP), procedures like inguinal hernia repair and thoracic surgery, leg amputation, and coronary artery bypass surgery are at higher risk due to potential nerve damage. Surgical techniques that minimize nerve injury are critical to reducing this risk. Postoperative pain is categorized as acute (up to 7 days post-surgery) or chronic (lasting over 3 months), arising from cutaneous, deep somatic, or visceral structures.
"Postoperative Pain Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postoperative Pain Therapeutics Market.
Key Takeaways from the Postoperative Pain Pipeline Report
DelveInsight's Postoperative Pain pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment.
In August 2024, Mylan Specialty, LP announced that MR-107A-02 is being evaluated for its safety and efficacy in treating acute pain following herniorrhaphy.
In August 2024, Jiangsu HengRui Medicine Co., Ltd. disclosed an ongoing study to assess the safety and effectiveness of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgeries under real-world conditions.
In June 2024, Johnson & Johnson Consumer Inc. announced a study aimed at determining the effectiveness of a fixed-dose combination of acetaminophen and naproxen sodium compared to a placebo in reducing pain over a 48-hour period through multiple doses.
In March 2024, Formosa Pharmaceuticals and AimMax Therapeutics received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat postoperative inflammation and pain after ocular surgery.
Key Postoperative Pain companies such as Vivozon Pharmaceutical Inc., LipoCure, InSitu Biologics, and others are evaluating new drugs for Postoperative Pain to improve the treatment landscape.
Promising Postoperative Pain pipeline therapies in various stages of development include VVZ-149, LC-400, INSB-200, and others.
Postoperative Pain Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Postoperative Pain Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postoperative Pain treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postoperative Pain market.
Download our free sample report @ https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Postoperative Pain Companies
There are approx. 45+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Vivozon Pharmaceutical Inc.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Tropical
Postoperative Pain Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Download Sample Pages to Get an in-depth Assessment of the Emerging Postoperative Pain Therapies and Key Companies: Postoperative Pain Clinical Trials and advancements https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Postoperative Pain Pipeline Therapeutic Assessment
• Postoperative Pain Assessment by Product Type
• Postoperative Pain By Stage
• Postoperative Pain Assessment by Route of Administration
• Postoperative Pain Assessment by Molecule Type
Download Postoperative Pain Sample report to know in detail about the Postoperative Pain treatment market @ Postoperative Pain Therapeutic Assessment https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Postoperative Pain Current Treatment Patterns
4. Postoperative Pain - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Postoperative Pain Late-Stage Products (Phase-III)
7. Postoperative Pain Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Postoperative Pain Discontinued Products
13. Postoperative Pain Product Profiles
14. Postoperative Pain Key Companies
15. Postoperative Pain Key Products
16. Dormant and Discontinued Products
17. Postoperative Pain Unmet Needs
18. Postoperative Pain Future Perspectives
19. Postoperative Pain Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Postoperative Pain Pipeline Reports Offerings: https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
8 hours ago
- National Post
KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai
Article content New organizational structure will drive commercial growth, innovation, and overall business performance. Article content EL SEGUNDO, Calif. — KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Article content Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development, and manufacturing under a unified leadership structure for the region. Article content The formation of KARL STORZ North America reflects the company's commitment to enhancing operational efficiency, service, and value to its customers across a broader geographic footprint. Article content 'After 80 years, KARL STORZ's mission remains the same – to improve patient lives,' said Matai, President of KARL STORZ North America. 'The decision to unify our businesses across North America underscores our commitment to our customers and their evolving needs in patient care. This is an exciting opportunity to leverage exceptional talent from both countries, which will only strengthen our ability to bring solutions to market with greater speed and agility.' Article content Effective today, KARL STORZ North America encompasses six locations in the US and a Canadian and Veterinary hub in Mississauga, Ontario, a region recognized for its booming medical technology sector. Changes to the organizational structure will cause no anticipated disruption to services, product availability, or customer support. Article content About KARL STORZ Article content KARL STORZ is an innovative leader in endoscopic technology and surgical imaging solutions across virtually all surgical specialties. Its integrated OR solutions, including advancements in digital surgery, enhance collaboration to improve clinical efficiency and outcomes inside the hospital and across other sites of care. With subsidiaries around the world, KARL STORZ is a family-owned company based in Germany that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit Article content Article content Article content
Globe and Mail
9 hours ago
- Globe and Mail
Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Neurofibromatoses Pipeline Insight, 2025 ' report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neurofibromatoses pipeline landscape. It covers the Neurofibromatoses pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibromatoses pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Neurofibromatoses Treatment Landscape. Click here to read more @ Neurofibromatoses Pipeline Outlook Key Takeaways from the Neurofibromatoses Pipeline Report In June 2025, Healx Limited announced a phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN. In June 2025, Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib. DelveInsight's Neurofibromatoses pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neurofibromatoses treatment. The leading Neurofibromatoses Companies such as Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Promising Neurofibromatoses Pipeline Therapies such as trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others. Discover groundbreaking developments in Neurofibromatoses Therapies! Gain in-depth knowledge of key Neurofibromatoses emerging drugs, and market opportunities @ Neurofibromatoses Clinical Trials Assessment Neurofibromatoses Emerging Drugs Profile FCN-159: Shanghai Fosun Pharmaceutical FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK). It is being developed by Fochon as a monotherapy and in combination to treat solid tumors. MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS. Currently, the drug is in Phase III stage of its development for the treatment of Neurofibromatoses. HLX-1502: Healx Limited HLX-1502 is an investigational, orally administered small molecule drug developed by Healx for treating Neurofibromatosis Type 1 (NF1), a rare genetic disorder marked by tumor growth along nerves. HLX-1502 was discovered using Healx's proprietary AI platform, which accelerates the identification of potential drug candidates. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance for the NF1 community. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Neurofibromatosis Type 1. PAS-004: Pasithea Therapeutics Corp. PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Currently, the drug is in the Phase I stage of its development for the treatment of Neurofibromatosis Type 1. The Neurofibromatoses Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatoses with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatoses Treatment. Neurofibromatoses Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Neurofibromatoses Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatoses market Stay informed about the Neurofibromatoses pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Neurofibromatoses Unmet Needs Neurofibromatoses Companies Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Neurofibromatoses Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Neurofibromatoses Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Neurofibromatoses Pipeline! See the latest progress in drug development and clinical research @ Neurofibromatoses Market Drivers and Barriers, and Future Perspectives Scope of the Neurofibromatoses Pipeline Report Coverage- Global Neurofibromatoses Companies- Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Neurofibromatoses Pipeline Therapies- Trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others. Neurofibromatoses Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Neurofibromatoses Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Neurofibromatoses Pipeline Analysis Today! @ Neurofibromatoses Drugs and Companies Table of Contents Introduction Executive Summary Neurofibromatoses: Overview Pipeline Therapeutics Therapeutic Assessment Neurofibromatoses– DelveInsight's Analytical Perspective Late Stage Products (Phase III) FCN-159: Shanghai Fosun Pharmaceutical Drug profiles in the detailed report….. Mid Stage Products (Phase II) HLX-1502: Healx Limited Drug profiles in the detailed report….. Early Stage Products (Phase I) PAS-004: Pasithea Therapeutics Corp. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Neurofibromatoses Key Companies Neurofibromatoses Key Products Neurofibromatoses- Unmet Needs Neurofibromatoses- Market Drivers and Barriers Neurofibromatoses- Future Perspectives and Conclusion Neurofibromatoses Analyst Views Neurofibromatoses Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
National Post
9 hours ago
- National Post
IKS Health Announces Transformational Partnership with Western Washington Medical Group through Strategic Investment in Managed Service Organization
Article content DALLAS — IKS Health, a global leader in care enablement solutions supporting clinicians, staff and patients throughout the care journey, is pleased to announce a transformative expansion of its partnership with Western Washington Medical Group (WWMG), a leading independent multispecialty healthcare organization in Washington state. Article content IKS Health will make a strategic investment in a newly established management services organization (MSO) that will oversee all nonclinical operations of WWMG, including revenue cycle management, clinical documentation, HR, IT and finance. The clinical operations will continue to reside within WWMG, allowing for a clear separation of clinical and administrative functions. Article content Article content As part of this expanded partnership, IKS Health will support WWMG through the newly formed MSO, helping the medical group improve performance across both fee-for-service and value-based care models. By addressing key administrative and operational functions, IKS will position WWMG to better manage risk-based populations, reduce friction in care delivery and improve financial sustainability and patient outcomes. Article content This support will be powered by IKS Health's comprehensive, AI-enabled care enablement platform. WWMG will gain access to advanced revenue cycle management, clinical documentation through the Scribble Suite's ambient scribing solution and a patient engagement hub driven by a patent-pending AI algorithm that predicts and reduces no-shows while improving communication across the care journey. Additional services include chart reviews, document management and care coordination. Article content 'Our work with IKS Health has resulted in streamlined operations and increased efficiencies, leading us to expand our partnership and further position us for growth and, most importantly, for providing excellent patient care,' said David Russian, M.D., CEO of Western Washington Medical Group. 'This strategic partnership with IKS Health will create transformational value for WWMG with a self-sustaining model for independent medicine that benefits all stakeholders — clinicians, patients and the communities that we serve.' Article content 'Our initial investment of substantial capital into the MSO reflects our strong conviction in the long-term potential of this partnership,' said Joe Benardello, co-founder and chief growth officer at IKS Health. 'The investment will be used to grow WWMG's physician base and expand its primary care capacity. When combined with the operational efficiencies driven by the IKS Health platform, it lays the foundation for scalable and sustainable growth.' Article content 'This partnership marks a pivotal step in IKS's journey to lead the strategic transformation of healthcare,' said Sachin K. Gupta, founder and CEO of IKS Health. 'It moves us meaningfully up the value chain, well beyond commoditized point solutions, and creates a scalable and replicable path to growth. By enabling a sustainable model for physician aggregation that delivers on the quadruple aim, we're not only unlocking two powerful pools of economic value (revenue from the IKS platform and long term value from the MSO growth) — we're also deepening the moat around our Care Enablement Platform and reinforcing our long-term relevance in an increasingly dynamic healthcare landscape.' Article content About Western Washington Medical Group Article content Western Washington Medical Group (WWMG) is a team of over 100 providers in 20+ specialty areas serving patients and their families in the north Puget Sound region of Washington State. Their providers are owners of the company, and they live and work in the communities that they serve. For over 30 years, it's been WWMG's mission to provide clinicians the freedom to practice medicine with compassion, in the best interest of their patients and community. Learn more at Article content About IKS Health Article content IKS Health takes on the chores of healthcare — spanning administrative, clinical, and operational burdens — so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS Health enables stronger, financially sustainable enterprises. IKS Health's Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS Health is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS Health's global workforce supports large health systems across the United States. For more information on IKS Health and its solutions, please visit Article content Article content Article content Article content Article content Article content
